EPSTI1 Inhibitors
Chemical inhibitors of EPSTI1 can be understood by analyzing their mode of action within the cellular signaling pathways. Staurosporine, a potent protein kinase inhibitor, can inhibit EPSTI1 activity by blocking phosphorylation events that EPSTI1 may require for its function. Similarly, LY294002 and Wortmannin target PI3K, thereby reducing downstream AKT signaling which could be crucial for EPSTI1's role in cellular processes. By inhibiting PI3K, these chemicals prevent the subsequent activation of AKT, potentially leading to a decrease in EPSTI1 activity. Moreover, U0126 and PD98059, which are specific inhibitors of MEK, can suppress the MAPK/ERK pathway, a pathway that might regulate EPSTI1. By preventing the activation of ERK, these inhibitors could reduce the functional activity of EPSTI1.
In addition to these, SP600125 and SB203580 focus on inhibiting the JNK and p38 MAPK pathways, respectively. By doing so, SP600125 can prevent the JNK-mediated signaling processes that EPSTI1 may be involved in, while SB203580 can decrease EPSTI1 activity by blocking the p38 MAPK route. Rapamycin and AZD8055 are inhibitors of mTOR, an integral part of the PI3K/AKT pathway which could impact EPSTI1 functionality by regulating protein synthesis and function. The inhibition of mTOR by these chemicals can lead to a reduction in EPSTI1 activity. Furthermore, PP2 and Dasatinib inhibit Src family kinases and other tyrosine kinases, which are key players in multiple signaling pathways that may involve EPSTI1. By blocking these kinases, PP2 and Dasatinib can prevent the phosphorylation of proteins that interact with or regulate EPSTI1, leading to a decrease in its activity. Imatinib, another tyrosine kinase inhibitor, can also decrease EPSTI1 activity by inhibiting the kinases such as BCR-ABL, c-KIT, and PDGFR that potentially regulate EPSTI1 function through tyrosine kinase-dependent signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. EPSTI1 is implicated in signal transduction pathways, and staurosporine can inhibit these pathways, leading to a functional inhibition of EPSTI1 activity by preventing its phosphorylation or the phosphorylation of proteins that interact with EPSTI1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. PI3K is involved in the AKT signaling pathway, which can regulate the activity of various proteins including EPSTI1. Inhibition of PI3K will therefore decrease AKT activity, which could lead to reduced function of EPSTI1 as part of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathways. JNK influences various cellular functions, potentially including those involving EPSTI1. By inhibiting JNK, SP600125 could reduce the functional activity of EPSTI1 that relies on JNK-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a known inhibitor of p38 MAPK. The p38 MAPK signaling pathway may regulate EPSTI1 function, and inhibition of p38 MAPK by SB203580 could lead to a decrease in EPSTI1 activity if EPSTI1 relies on this pathway for its action. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, similar to LY294002. By inhibiting PI3K, wortmannin would lead to a decrease in downstream signaling through AKT, potentially decreasing the functional activity of EPSTI1 if it is part of the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of ERK. As EPSTI1 could be dependent on the MAPK/ERK pathway for its function, inhibition of this pathway by PD98059 would lead to a decrease in EPSTI1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since mTOR is a key component of the PI3K/AKT pathway, which can regulate protein synthesis and function, rapamycin can inhibit the functional activity of proteins involved in this pathway, potentially including EPSTI1. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Src kinases can be involved in multiple signaling pathways that regulate various cellular processes, some of which may involve EPSTI1. Inhibition by PP2 could therefore decrease the functional activity of EPSTI1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad inhibitor of tyrosine kinases, including Src family kinases. Given the role of these kinases in signaling pathways, dasatinib's inhibition of these kinases could lead to reduced function of EPSTI1 if it is involved in tyrosine kinase-dependent signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, known to inhibit BCR-ABL, c-KIT, and PDGFR. Tyrosine kinase signaling can be crucial for the function of proteins like EPSTI1, and inhibition by imatinib could lead to a reduction in EPSTI1 activity within these signaling contexts. | ||||||